Heres why: Even though injectable GLP-1s still lead on clinical efficacy (15 and 20% weight loss with Wegovy and Zepbound respectively) and dominate the market to date, theres a segment of patients who would prefer an oral option over self-injections
IFG/IGT 29.55.5
This performance was driven by sustained demand for therapies targeting serious conditions, particularly Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis)
Neupane R, Boddu SHS, Renukuntla J, Babu RJ, Tiwari AK
so every bite needs to do more
Besides, after an induced traumatic brain injury in mice, BPC 157 regimens (corresponding to those used in the present study) demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24 h post-injury period